Chemical formula: C₂₆H₂₈N₂ Molecular mass: 368.524 g/mol PubChem compound: 2761
Cinnarizine interacts in the following cases:
There have been no specific studies in hepatic or renal dysfunction. Cinnarizine should be used with care in patients with hepatic or renal insufficiency.
Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either these drugs or of cinnarizine.
Use of cinnarizine should be avoided in porphyria.
In patients with Parkinson’s Disease, cinnarizine should only be given if the advantages outweigh the possible risk of aggravating this disease.
The safety of cinnarizine in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. As with other drugs it is not advisable to administer cinnarizine in pregnancy.
There are no data on the excretion of cinnarizine in human breast milk. Use of cinnarizine is not recommended in nursing mothers.
Cinnarizine may cause drowsiness, especially at the start of treatment; patients affected in this way should not drive or operate machinery.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
